Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KDTFA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
F0002-ADC
|
|||||
| Synonyms |
CD30-MCC-DM1; F0002 ADC; F-0002-ADC
Click to Show/Hide
|
|||||
| Organization |
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 2 Indication(s)
Anaplastic large cell lymphoma [ICD11:2A90]
Phase 1
Cutaneous T-cell lymphoma [ICD11:2B00]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
3.37
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Emtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.